According to the provided sources, the patent for Ozempic is set to expire in 2032. Ozempic is a medication used for the treatment of type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and is manufactured by Novo Nordisk.

The first source, Drug Patent Watch, confirms that the patent for Ozempic is set to expire on October 25, 2032 [1]. This information is further supported by the second source, BioSpace, which includes Ozempic in its list of drugs losing patents or exclusivity clauses by the end of 2023 [2]. However, it is important to note that the expiration date provided in the second source may not be accurate, as it conflicts with the information from the first source.

Additionally, the third source, FiercePharma, provides a list of top 15 blockbuster patent expirations coming in the next decade. While Ozempic is not specifically mentioned in this list, it gives an overview of major patent expirations in the pharmaceutical industry [3].

In conclusion, based on the provided sources, the patent for Ozempic is set to expire in 2032. It is always recommended to consult official sources or contact the manufacturer directly for the most up-to-date and accurate information regarding patent expirations.

Sources:
[1] Drug Patent Watch: Ozempic Patent Expiration Information. Retrieved from https://www.drugpatentwatch.com/p/tradename/OZEMPIC
[2] BioSpace: 9 Drugs Losing Patents or Exclusivity Clauses by the End of 2023. Retrieved from https://www.biospace.com/article/9-drugs-losing-patents-or-exclusivity-clauses-by-the-end-of-2023/
[3] FiercePharma: Top 15 blockbuster patent expirations coming in the next decade. Retrieved from https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade